Our experience and expertise in translational medicine, immunology, and the design and execution of rapid go/no-go clinical trials makes us a unique development partner in the field of immune-mediated disease. We leverage this distinctive drug development strategy to advance our carefully selected portfolio of product candidates and identify opportunities to in-license additional development assets that align with our paradigm of intercepting and preventing autoimmune and inflammatory diseases.

Our current partners include Janssen, Amgen, MacroGenics and Vactech.